Invivyd Inc. Launches New Discovery Program for Monoclonal Antibody Treatment Targeting Measles Infections
I'm PortAI, I can summarize articles.
Invivyd Inc. has launched a new discovery program aimed at developing a monoclonal antibody treatment for measles infections. This initiative responds to healthcare providers' requests for therapeutic options due to declining vaccination rates, with over 20 million Americans unvaccinated. The program seeks to identify a preclinical candidate by 2025, with updates expected by year-end. This effort is part of Invivyd's broader research into monoclonal antibodies for COVID-19, RSV, and influenza.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments